Phase I Clinical Study of Crenezumab in Patients with Alzheimer's Disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223155

Enrollment

Registered

2016-03-31

Start date

2016-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease(AD)

Interventions

investigational material(s) Generic name etc : Crenezumab INN of investigational material : Crenezumab Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Diagnosed as having probable AD dementia based on the NIA-AA core diagnostic criteria, or diagnosed as having mild to moderate dementia due to AD based on DSM-V -MMSE score is 18 to 28 at screening etc.

Exclusion criteria

Exclusion criteria: -Concurrent neurological disease other than AD that could affect cognitive function or history thereof. -Meet the exclusion criteria of MRI at screening. etc.

Design outcomes

Primary

Measure	Time frame
safety Observation/examination	—

Secondary

Measure	Time frame
pharmacokinetics other Observation/examination	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026